Radiopharmaceutical Laboratory Design & USP <825> Standards

ABMP Medical Health Physics Exam

Track your progress as you read

Finished sections get a check mark.

1 Radiation Detection Instrumentation

Ionization Chambers & Geiger-Mueller Counters Scintillation Detectors, Photomultipliers & Gamma Spectroscopy Liquid Scintillation & Gamma Counting Systems: Well Counters & Thyroid Probes Personnel Dosimeters & Electronic Radiation Monitors Neutron Detection & Emergency Field Instrumentation

2 Laboratory Design & Contamination Control

Radiopharmaceutical Laboratory Design & USP <825> Standards Ventilation Systems, Fume Hoods & Contamination Engineering

3 Radiation Protection Standards & Dose Limits

Federal Regulatory Framework & Advisory Authorities Federal Guidance Documents: NRC Regulatory Guides, NUREGs, EPA & FDA Guidance Occupational & Public Dose Limits and ALARA Principles Radiobiological Basis of Limits & Risk Communication

4 Medical Licensing, Written Directives & Security

NRC Form 313 Authorizations, RSO Responsibilities & Written Directives Medical Event Reporting & 10 CFR 37 Category 1/2 Source Security

5 Diagnostic Radiology Structural Shielding

Diagnostic Shielding Methodology: NCRP Report 147 Modality Shielding: Radiography, Fluoroscopy & CT Facilities

6 Megavoltage Therapy Vault & Facility Shielding

Megavoltage Vault Primary & Secondary Barriers: NCRP Report 151 Therapy Maze Design, Photoneutrons & Shielded Doors PET/CT & Nuclear Medicine Facility Shielding (AAPM TG-108)

7 Radiation Oncology Quality Management & Safety

External Beam QA & Dosimetry Calibration Protocols Brachytherapy Safety, Inventory Control & Leak Testing

8 Radiation Oncology Emergency Procedures & TPS QA

Treatment Planning System (TPS) QA & Patient Verification Radiation Oncology Emergency Procedures: HDR Stuck Sources & Linac Failures Medical Events, Incident Investigation & Joint Commission Requirements in Radiation Oncology

9 Diagnostic Imaging Safety & Fluoroscopy Management

Diagnostic X-ray & Fluoroscopy Safety Interventional Fluoroscopy Dose Management & NCRP Report 168

10 CT Optimization, MQSA & Diagnostic Accreditation

Computed Tomography Dosimetry & Protocol Optimization Mammography Quality Standards Act (MQSA) & Mammography Physics Diagnostic Imaging Quality Management, Accreditation & Regulatory Oversight

11 Nuclear Medicine Radiopharmacy & Unsealed Therapy

Radiopharmaceutical QC & Radionuclide Calibrators Unsealed Source Therapy: I-131 Protocols & Patient Release Criteria

12 Targeted Radionuclide Therapy, Decontamination & RAM Transport

Targeted Radionuclide Therapies: Lu-177, Ra-223, Y-90 & Radioimmunotherapy Contamination Surveys, Spill Response & Personnel Decontamination Radioactive Waste Disposal & US DOT Transport Regulations

13 Radiobiology & Radiation Risk Assessment

Cellular Radiobiology, DNA Damage & Dose-Response Models Prenatal Radiation Risks & Population Exposures

14 Non-Ionizing Radiation Safety: Lasers & MRI

Healthcare Laser Safety: ANSI Z136.1 & Z136.3 MRI Safety, Facility Design & Bioeffects

Radiopharmaceutical Laboratory Design & USP <825> Standards

Key Takeaways Explain This Topic AI

USP <825> governs the preparation, compounding, dispensing, and repackaging of radiopharmaceuticals, balancing aseptic technique with ALARA radiation protection.

Air quality follows ISO 14644-1: an ISO Class 5 primary engineering control (PEC) inside an ISO Class 7 buffer room entered through an ISO Class 8 ante-room, or an ISO 5 PEC inside a segregated radiopharmaceutical processing area (SRPA) with a maximum 12-hour BUD.

USP <825> requires at least 30 total HEPA-filtered ACPH in an ISO Class 7 buffer room (at least 15 ACPH from the HVAC through ceiling HEPA filters) and at least 20 ACPH in an ISO Class 8 ante-room; ACPH = (Q × 60) / V.

In a cleanroom suite the buffer room is held at least +0.020 in. w.c. relative to the ante-room, and the ante-room at least +0.020 in. w.c. relative to unclassified space; negative pressure for volatile radionuclides applies to the restricted area or SRPA under the radioactive materials license.

The buffer area may not contain sinks or floor drains and the ante-room may not contain floor drains; in an SRPA design the sink must be at least 1 m from the PEC and generators and outside the SRPA perimeter.

Last updated: October 2026

Radiopharmaceutical Laboratory Design & USP <825> Standards

Designing a clinical or centralized radiopharmaceutical laboratory presents an inherent engineering challenge: reconciling the strict aseptic requirements of pharmaceutical sterile compounding with the containment imperatives of radiation protection under ALARA (As Low As Reasonably Achievable). Traditional sterile drug compounding governed by United States Pharmacopeia (USP) General Chapter <797> relies on positive-pressure cleanroom suites to sweep airborne microbial particulates away from critical drug preparation sites. However, handling volatile or aerosolized unsealed radionuclides—such as sodium iodide ( 131 I ^{131}\text{I} 131 I ), xenon gas ( 133 Xe ^{133}\text{Xe} 133 Xe ), or alpha-emitting radioimmunotherapies—mandates negative-pressure containment to protect occupational personnel and the public from inhalation hazards. To resolve these contrasting priorities, the United States Pharmacopeial Convention established USP General Chapter <825> ( Radiopharmaceuticals—Preparation, Compounding, Dispensing, and Repackaging ), setting enforceable physical facility, environmental monitoring, and operational criteria specifically adapted to unsealed radioactive materials.

Cleanroom Zoning & ISO 14644-1 Air Quality Classifications

Under USP <825>, radiopharmaceutical manipulations must be segregated into clearly defined environmental zones based on ISO 14644-1 particulate cleanliness standards . Each boundary provides a successive barrier against microbial contamination while maintaining radiological containment.

Zone Designation ISO 14644-1 Class Maximum Particles (≥ 0.5 µm/m³) Typical Engineering Implementation Function & Activity Scope

Primary Engineering Control (PEC) ISO Class 5 ≤ 3,520 Class II Type B2 BSC, Compounding Aseptic Containment Isolator (CACI), or Hot Cell with laminar airflow Direct compounding, vial puncture, kit reconstitution, and sterile dispensing

Secondary Engineering Control (SEC) / Buffer Room ISO Class 7 ≤ 352,000 Cleanroom suite housing the PECs, supplied with terminal HEPA ceiling filters Controlled background atmosphere surrounding PECs; staging of sterile components

Ante-Room (Gowning / Transition) ISO Class 8 ≤ 3,520,000 Dedicated transition room between buffer room and unclassified hospital corridor Personnel garbing, hand hygiene, package decontamination, order review

Segregated Radiopharmaceutical Processing Area (SRPA) Unclassified Not specified (ambient) Demarcated area within the restricted area that contains an ISO Class 5 PEC; no ante-room required Dispensing, repackaging, kit preparation, and minor-deviation preparation with a maximum BUD of 12 hours

In an ISO Class 5 PEC , unidirectional laminar airflow sweeps across the critical compounding zone at a certified velocity of 90 fpm ± 20 % 90\text{ fpm} \pm 20\% 90 fpm ± 20% ( 0.45 m/s ± 20 % 0.45\text{ m/s} \pm 20\% 0.45 m/s ± 20% ). When volatile radionuclides are handled, the PEC should be a ducted, 100%-exhaust device so vapors are not recirculated into the room.

USP <825> Table 7 ties the beyond-use date (BUD) to the environment: immediate-use preparation carries a 1-hour BUD; dispensing, repackaging, kit preparation, and preparation with minor deviations in an ISO 5 PEC located in an SRPA may be assigned up to 12 hours; an ISO 5 PEC inside an ISO 8 buffer room with an ISO 8 ante-room allows up to 24 hours; and an ISO 5 PEC inside an ISO 7 (or cleaner) buffer room with an ISO 8 ante-room allows up to 96 hours. Generator elution in an SRPA meeting ISO 8 particle counts is limited to 12 hours.

HVAC Dynamics & Air Change Rates (ACPH)

Air quality in the buffer room and ante-room is maintained by continuous volumetric dilution using high-efficiency particulate air (HEPA) filtration. The operational metric governing contamination clearance is the Air Changes Per Hour (ACPH) :

ACPH = Q × 60 V \text{ACPH} = \frac{Q \times 60}{V} ACPH = V Q × 60 ​

where Q Q Q is the volumetric flow rate of HEPA-filtered supply air in cubic feet per minute ( CFM \text{CFM} CFM or ft 3 / min \text{ft}^3/\text{min} ft 3 / min ), V V V is the gross room volume in cubic feet ( ft 3 \text{ft}^3 ft 3 ), and 60 is the conversion factor from minutes to hours.

USP <825> Air-Change Minimums

ISO Class 7 Buffer Room : At least 30 total HEPA-filtered ACPH, of which at least 15 ACPH must come from the HVAC system through HEPA filters located in the ceiling (air recirculated by the PEC may make up the rest); returns are placed low on the walls.

ISO Class 8 Ante-Room : Minimum ≥ 20 ACPH total HEPA-filtered air.

Worked Engineering Example

A nuclear medicine department designs a new ISO Class 7 buffer room with dimensions 16 ft × 15 ft 16\text{ ft} \times 15\text{ ft} 16 ft × 15 ft and a finished ceiling height of 9.0 ft 9.0\text{ ft} 9.0 ft . The gross volume is:

V = 16 ft × 15 ft × 9.0 ft = 2 , 160 ft 3 V = 16\text{ ft} \times 15\text{ ft} \times 9.0\text{ ft} = 2,160\text{ ft}^3 V = 16 ft × 15 ft × 9.0 ft = 2 , 160 ft 3

To satisfy the mandatory 30 ACPH threshold, the minimum volumetric supply flow rate Q min Q_{\text{min}} Q min ​ is:

Q min = ACPH × V 60 = 30 hr − 1 × 2 , 160 ft 3 60 min/hr = 1 , 080 CFM Q_{\text{min}} = \frac{\text{ACPH} \times V}{60} = \frac{30\text{ hr}^{-1} \times 2,160\text{ ft}^3}{60\text{ min/hr}} = 1,080\text{ CFM} Q min ​ = 60 ACPH × V ​ = 60 min/hr 30 hr − 1 × 2 , 160 ft 3 ​ = 1 , 080 CFM

At least half of that rate (15 ACPH, or 540 CFM 540\text{ CFM} 540 CFM ) must be delivered by the HVAC system through ceiling HEPA filters. If the room also houses a Type B2 BSC that exhausts 650 CFM 650\text{ CFM} 650 CFM outdoors, the supply must also replace that exhausted air while still holding the buffer room positive to the ante-room.

Differential Pressure Cascades: Sterility vs. Containment

Directional airflow keeps lower-quality air from flowing into cleaner spaces. USP <825> resolves the conflict between sterility and radiation containment by assigning each goal to a different boundary.

What USP <825> Requires

Cleanroom suite (positive cascade) : Each ISO-classified room must be at least + 0.020 in. w.c. +0.020\text{ in. w.c.} + 0.020 in. w.c. ( ≈ + 5 Pa \approx +5\text{ Pa} ≈ + 5 Pa ) relative to the adjoining lower-classified room (buffer room to ante-room), and the ante-room must be at least + 0.020 in. w.c. +0.020\text{ in. w.c.} + 0.020 in. w.c. relative to the unclassified area. Differentials are monitored continuously and recorded on days of use.

Restricted-area containment : Where volatile or airborne radiopharmaceuticals are handled (for example, I-131 sodium iodide solution or Xe-133 gas), the restricted area (the hot lab) is kept negative relative to unrestricted areas. State inspection checklists built on <825> spell out the combination: buffer area positive to the ante-room, ante-room positive to unclassified parts of the restricted area, and the restricted area negative to unrestricted space when volatile material is present.

SRPA and hot lab : USP <825> does not set pressure differentials for an SRPA or an unclassified hot lab; those follow the conditions in the facility's radioactive materials license.

Note

The often-quoted "0.01 to 0.03 in. w.c. negative" buffer room comes from USP <800> for hazardous drugs. Radiopharmaceuticals are governed by USP <825>, so do not import the <800> negative buffer-room design into a <825> cleanroom suite.

Volatile radioiodine is therefore controlled at the source: therapeutic I-131 is usually purchased as capsules; liquid I-131 is opened and dispensed in a ducted, 100%-exhaust hood or hot cell with charcoal filtration; and xenon studies are done in rooms held negative to their surroundings with dedicated exhaust or a xenon trap.

Continuous differential-pressure monitors (calibrated gauges or digital transducers with data logging and alarms) are installed at the classified-room boundaries.

Architectural Engineering & Materials Specification

Every physical surface in a radiopharmacy must withstand harsh chemical disinfectants (e.g., sodium hypochlorite, quaternary ammonium compounds, 70% sterile isopropanol) while permitting effective radioactive decontamination without surface degradation.

Flooring Systems : Monolithic, seamless sheet vinyl with heat-welded joints or self-leveling poured aliphatic polyurethane/epoxy. Floor-to-wall junctions are coved or sealed, because sharp 90-degree corners trap dust, radioactive particulates, and moisture. USP <825> requires classified-area surfaces to be smooth, impervious, free from cracks and crevices, and non-shedding so they can be cleaned and disinfected.

Wall and Ceiling Assemblies : Hard-surfaced gypsum board coated with scrubbable, chemical-resistant high-build two-part epoxy paint. Porous lay-in acoustic tiles are unsuitable in classified rooms; if ceiling panels are used, they are sealed (caulked or gasketed) to the frame so pressure changes cannot pull plenum dust into the room.

Workstations & Benchtops : Heavy-gauge Type 316 stainless steel or non-porous solid epoxy resins. A raised lip around bench edges helps contain liquid spills.

Sinks and Floor Drains (USP <825> section 5.3) : The buffer area must not contain sinks or other plumbed water sources or floor drains, and the ante-room must not contain floor drains. The hand-hygiene sink may be inside the ante-room or outside it in a clean space. In an SRPA design the sink must be accessible but at least 1 m from the PEC and any generators , and not inside the SRPA perimeter. Drains and traps hold stagnant moisture that harbors waterborne organisms such as Pseudomonas aeruginosa .

Structural Shielding Integration & Decay Storage Vaults

Radiopharmacy shielding must integrate massive attenuation materials directly into cleanroom architecture without disrupting laminar airflow or exceeding structural building limits.

Floor Loading

Hot cells and dispensing stations for positron emitters ( 18 F ^{18}\text{F} 18 F , 68 Ga ^{68}\text{Ga} 68 Ga , 11 C ^{11}\text{C} 11 C ; 511 keV 511\text{ keV} 511 keV annihilation photons) use several centimetres of lead plus lead-glass viewing windows, so a fully shielded cell weighs several tonnes. The physicist and a structural engineer should confirm floor loading before installation; ground-floor slabs or added structural support are common solutions.

Decay-in-Storage (DIS) Area Layout

Under 10 CFR 35.92, byproduct material with a physical half-life of T 1 / 2 ≤ 120 days T_{1/2} \le 120\text{ days} T 1/2 ​ ≤ 120 days may be held for decay-in-storage. The rule sets no fixed holding time: before disposal the material must be indistinguishable from background at its surface, measured with an appropriate survey meter on its most sensitive scale with no interposed shielding, and radiation labels must be removed or obliterated (except labels on material inside containers that will be managed as biomedical waste). Good design therefore includes:

Shielding sized so adjacent areas meet the 10 CFR 20.1301 public limits (1 mSv per year, and no more than 0.02 mSv in any one hour in unrestricted areas).

Segregated, dated containers grouped by half-life so short-lived waste is not held up behind longer-lived waste.

A low-background location where the release survey can be done.

Ergonomic Shielding: Tungsten vs. Lead

Syringe shields and vial transport pigs must optimize radiation attenuation per unit volume. Elemental tungsten offers a physical density of ρ W ≈ 19.3 g/cm 3 \rho_{\text{W}} \approx 19.3\text{ g/cm}^3 ρ W ​ ≈ 19.3 g/cm 3 , compared to lead at ρ Pb ≈ 11.34 g/cm 3 \rho_{\text{Pb}} \approx 11.34\text{ g/cm}^3 ρ Pb ​ ≈ 11.34 g/cm 3 . At 140 keV 140\text{ keV} 140 keV ( 99 m Tc ^{99\text{m}}\text{Tc} 99 m Tc ) and 511 keV 511\text{ keV} 511 keV (PET isotopes), tungsten provides the same attenuation with roughly 25% to 35% less thickness than lead (its mass attenuation coefficient is slightly lower than lead's, but its density is 70% higher), substantially reducing syringe bulk, improving dexterity, and lowering hand fatigue and extremity doses during high-throughput compounding.

• Clinical Scenarios & Health Physics Pitfalls
• Clinical Transition Scenario

A community medical center plans to expand its nuclear pharmacy to compound unsealed therapeutic 131 I ^{131}\text{I} 131 I sodium iodide capsules ( 150 mCi 150\text{ mCi} 150 mCi per capsule) alongside existing 99 m Tc ^{99\text{m}}\text{Tc} 99 m Tc diagnostic kits. The facility currently operates a single positive-pressure buffer room compliant with USP <797>. The Medical Health Physicist must point out that USP <825> still expects the cleanroom suite to cascade positively, so volatile I-131 cannot be made safe by reversing the buffer-room pressure. Containment is built around the source instead: buy the therapeutic I-131 as capsules where possible; if liquid must be handled, open and dispense it in a ducted, 100%-exhaust ISO 5 hot cell or containment isolator with charcoal filtration; keep the restricted hot-lab area negative to unrestricted corridors as the radioactive materials license requires; and add air sampling and thyroid bioassay for the staff who handle it.

Critical Health Physics Pitfalls

Placing Lead Bricks in Laminar Flow Benches : Stacking lead bricks inside an ISO Class 5 horizontal or vertical LAFW disrupts unidirectional airflow, generating downstream turbulence, stagnant eddies, and shedding lead oxide dust onto sterile critical sites.

Sinks in Sterile Buffer Suites : Installing a hand sink or eyewash drain inside an ISO Class 7 buffer room violates USP <825> section 5.3 and invites microbial colonization of plumbing traps.

Ignoring Air Supply Deflections : High-velocity ceiling diffusers blowing directly across the open sash of an ISO Class 5 BSC induce face turbulence and containment breach, spilling airborne activity into the room.